First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Официальное название

First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ALN-SOD in Participants With Amyotrophic Lateral Sclerosis and SOD1 Mutations

Обзор

This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This is the first time that ALN-SOD will be given to people. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: * The effect the study drug has on specific biomarkers, which are substances in the blood or in the fluid that surrounds the brain and spinal cord, known as Cerebrospinal Fluid (CSF) * How much study drug is in the blood and in the CSF, at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) * What effects the study drug has on ALS symptoms

Вмешательства

• Препарат ALN-SOD
  Administered per the protocol
• Другое Diluent
  Administered per the protocol
• Препарат Placebo (PB)
  Administered per the protocol

Первичные конечные точки

• Incidence of Treatment-Emergent Adverse Event (TEAEs) in participants treated with ALN-SOD [Срок оценки: At week 4 and through week 228]
• Severity of TEAEs in participants treated with ALN-SOD [Срок оценки: At week 4 and through week 228]

Вторичные конечные точки (11)

• Concentration of Neurofilament Light chain (NfL) in plasma over time [Срок оценки: Up to approximately week 228]
• Change in concentration of NfL in plasma over time [Срок оценки: Up to approximately week 228]
• Concentration of SOD1 protein in Cerebrospinal Fluid (CSF) over time [Срок оценки: Up to approximately week 228]
• Change in concentration of SOD1 protein in CSF over time [Срок оценки: Up to approximately week 228]
• Concentration of NfL in CSF over time [Срок оценки: Up to approximately week 228]
• Change in concentration of NfL in CSF over time [Срок оценки: Up to approximately week 228]
• Change in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) over time [Срок оценки: Up to approximately week 228]
• Concentration of ALN-SOD in plasma over time [Срок оценки: Up to approximately week 228]
• Concentration of ALN-SOD in CSF over time [Срок оценки: Up to approximately week 228]
• Incidence of Anti-Drug Antibodies (ADAs) to ALN-SOD in serum over time [Срок оценки: Up to approximately week 228]
• Titer of ADAs to ALN-SOD in serum over time [Срок оценки: Up to approximately week 228]

Критерии участия

Критерии включения

• Weakness attributable to ALS and a SOD1 variant that has been previously described as associated with ALS or is considered likely to cause ALS, as defined in the protocol
• Slow Vital Capacity (SVC) ≥50% predicted value based on age, gender and height, measured in upright position
• Body Mass Index (BMI) ≤35 kg/m2 at time of screening
• If participants are taking riluzole or edaravone, they must be on a stable dose for at least 4 weeks prior to initial dosing visit and are expected to remain at that dose until the end of the study
• Platelet count >50,000/microliter
• Has normal blood pressure readings, as defined in the protocol

Критерии исключения

• Concurrent participation in another interventional clinical trial
• Has had a tracheostomy
• Has dementia, as assessed by the investigator
• Has uncontrolled psychiatric disease, including psychosis, active or recent suicidal ideation, untreated major depression, in the past 30 days
• Has a medical history of brain or spinal disease/injury that would interfere with the Lumbar Puncture (LP) process, CSF circulation or safety assessment, as defined in the protocol
• Presence of an implanted shunt for the drainage of CSF or an implanted Central Nervous System (CNS) catheter
• Presents any concern to the study investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study
• Was hospitalized (ie, >24 hours) for any reason other than ALS within 30 days of screening
• Has received treatment with tofersen within 6 months prior to screening

NOTE: Other protocol defined inclusion / exclusion criteria apply

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Последовательный дизайн

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Канада · 4 центра

• University of Alberta Hospital, Edmonton, Division of Neurology — Edmonton
• University Hospital - London Health Sciences Centre — London
• Sunnybrook Research Institute — Toronto
• Montreal Neurological Institute and Hospital — Montreal

Япония · 4 центра

• Hokkaido University Hospital — Sapporo
• Tokushima University Hospital — Tokushima
• Toho University Omori Medical Center — Ōta-ku
• Kyoto University Hospital — Kyoto

Австралия · 3 центра

• Concord Repatriation General Hospital — Concord
• Macquarie University — Sydney
• Sunshine Coast University Hospital — Birtinya

Польша · 2 центра

• Medical University of Silesia — Zabrze
• MTZ Clinical Research powered by Pratia — Warsaw

South Korea · 2 центра

• Hanyang University Seoul Hospital — Seoul
• Seoul National University Hospital — Seoul

Тайвань · 2 центра

• Kaohsiung Chang Gung Memorial Hospital — Kaohsiung City
• Taipei Veterans General Hospital — Taipei

Бельгия · 1 центр

• KU Leuven — Leuven

Германия · 1 центр

• Universitaetsklinikum Ulm AoR — Ulm

Швеция · 1 центр

• Noorlands University Hospital-Department of Neurology — Umeå

Идентификаторы

NCT: NCT06351592 · ALN-SOD-ALS-2351 · 2023-510344-20-00

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗